Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index

This is the authors' abstract. We don't add key points for this paper.

Accurate measurement of disease activity in systemic sclerosis (SSc) remains a significant clinical challenge. The Scleroderma Clinical Trials Consortium (SCTC) convened an Activity Index (AI) Working Group (WG) to develop a novel measure of disease activity (SCTC-AI).